Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of CM559 in Healthy Subjects
Sponsor: Keymed Biosciences Co.Ltd
Summary
This study is a single center, randomized, double-blind, placebo-controlled, single dose, dose escalation Phase I clinical study aimed at evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM559 administered intravenously at different doses in healthy male subjects.
Official title: A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CM559 in Healthy Subjects With Single Ascending Dose Administration
Key Details
Gender
MALE
Age Range
18 Years - 60 Years
Study Type
INTERVENTIONAL
Enrollment
40
Start Date
2025-09
Completion Date
2026-06
Last Updated
2025-09-29
Healthy Volunteers
Yes
Conditions
Interventions
Placebo
Placebo injection administered IV, once.
CM559
CM559 injection administered IV, once.
Locations (1)
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China